Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
- Guidelines Specify that Validated Molecular Assays Should be Considered as an Adjunct to Standard Measures in Helping Determine Chemotherapy Benefit -
According to the guidelines, the threshold for recommending chemotherapy in treating estrogen receptor (ER) positive, HER2-negative breast cancer is difficult to define. Clinical research in
Oncotype DX was launched in
“We are pleased that the prestigious St. Gallen International Consensus recognizes the benefit that validated genomic tests, such as Oncotype DX, can offer to patients diagnosed with early stage breast cancer,” said
Aiming to provide evidence-based, scientifically valid recommendations for the treatment of early breast cancer in clinical practice, the St. Gallen consensus guidelines are determined bi-annually by a panel of more than 30 breast cancer experts from around the world. This is the first time that a European body of experts has supported the use of a validated multigene-profiling assay as an adjunct to high-quality phenotyping of breast cancer in cases where the indication for adjuvant chemotherapy is uncertain.
“These new guidelines provide further evidence that the international clinical community sees the value of advanced molecular diagnostics in helping make more informed, individualized breast cancer treatment decisions,” said Dr.
About Oncotype DX(R)
The Oncotype DX breast cancer assay is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. The Oncotype DX breast cancer assay has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, more than 8,000 physicians have ordered more than 100,000 tests in over 40 countries.
About Genomic Health
Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health is preparing to launch its Oncotype DX colon cancer test in early 2010. The company was founded in 2000 and is located in
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s belief that inclusion of the use of validated multigene assays such Oncotype DX in the St. Gallen guidelines supports the expansion of Oncotype DX in
SOURCE Genomic Health, Inc.